KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Amneal Pharmaceuticals (AMRX) Other Non Operating Income (2017 - 2026)

Amneal Pharmaceuticals has reported Other Non Operating Income over the past 9 years, most recently at -$1.4 million for Q4 2025.

  • For Q4 2025, Other Non Operating Income fell 76.32% year-over-year to -$1.4 million; the TTM value through Dec 2025 reached $1.9 million, down 78.17%, while the annual FY2025 figure was $7.6 million, N/A changed from the prior year.
  • Other Non Operating Income for Q4 2025 was -$1.4 million at Amneal Pharmaceuticals, down from $1.2 million in the prior quarter.
  • Over five years, Other Non Operating Income peaked at $6.9 million in Q2 2022 and troughed at -$40.2 million in Q4 2023.
  • A 5-year average of -$1.7 million and a median of $543500.0 in 2022 define the central range for Other Non Operating Income.
  • Biggest five-year swings in Other Non Operating Income: tumbled 18834.48% in 2022 and later skyrocketed 945.56% in 2024.
  • Year by year, Other Non Operating Income stood at -$9.1 million in 2021, then skyrocketed by 106.29% to $569000.0 in 2022, then tumbled by 7162.92% to -$40.2 million in 2023, then surged by 97.97% to -$815000.0 in 2024, then crashed by 76.32% to -$1.4 million in 2025.
  • Business Quant data shows Other Non Operating Income for AMRX at -$1.4 million in Q4 2025, $1.2 million in Q3 2025, and $1.6 million in Q2 2025.